With its once-biggest seller Velcade bracing for generics, Takeda’s hoping to grow its follow-up drug Ninlaro into a blockbuster. But the drug fell short in a systemic light-chain AL amyloidosis analysis—and the company decided to give up on the trial altogether.
![Het beste uit je content halen met een kloppend verhaal [10 stappen]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/businesswoman-working-at-creative-office-2023-11-27-05-24-05-utc-1-80x60.jpg)
